Premium
Identification of glycinexylidide in patients treated with intravenous lidocaine
Author(s) -
Strong John M.,
Parker Michele,
Atkinson Arthur J.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt197314167
Subject(s) - lidocaine , urine , metabolite , medicine , anesthesia , local anesthetic , toxicity , plasma concentration , pharmacology
Glycinexylidide (GX) has been identified in the urine of 8 patients treated with intravenous infusions of lidocaine. The concentration of GX ranged from 1.0 to 2.7 Ilg per milliliter in the plasma of 3 of these patients. This di‐desethylated product of lidocaine metabolism, like the mono‐desethylated metabolite, monoethylglycinexylidide (MEGX) also has local anesthetic activity. Both compounds may contribute to central nervous system (CNS) toxicity in some patients treated with lidocaine.